Global Market Direct's pharmaceuticals report, "Gilead Sciences, Inc. - Product Pipeline Review - Q4 2010" provides data on the company's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Gilead Sciences, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Gilead Sciences, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Gilead Sciences, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Gilead Sciences, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Gilead Sciences, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Gilead Sciences, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Gilead Sciences, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Gilead Sciences, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Gilead Sciences, Inc. and identify potential opportunities in those areas.

Contents:

List of Tables
List of Figures
Gilead Sciences, Inc. Snapshot
Gilead Sciences, Inc. Overview
Key Information
Key Facts
Gilead Sciences, Inc. - Research and Development Overview
Key Therapeutic Areas
Gilead Sciences, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Truvada + TMC 278
Product Description
Mechanism of Action
R&D Progress
Ambrisentan
Product Description
Mechanism of Action
R&D Progress
Azactam
Product Description
Mechanism of Action
R&D Progress
Cobicistat
Product Description
Mechanism of Action
R&D Progress
Darusentan
Product Description
Mechanism of Action
R&D Progress
Elvitegravir
Product Description
Mechanism of Action
R&D Progress
GS-9350 + Atazanavir + Emtricitabine + Tenofovir DF
Product Description
Mechanism of Action
R&D Progress
Perfan
Product Description
Mechanism of Action
R&D Progress
Quad
Product Description
Mechanism of Action
R&D Progress
Viread + Epivir + Sustiva
Product Description
Mechanism of Action
R&D Progress
Zerit + Epivir + Sustiva
Product Description
Mechanism of Action
R&D Progress
Azactam
Product Description
Mechanism of Action
R&D Progress
Cicletanine
Product Description
Mechanism of Action
R&D Progress
GS 9190
Product Description
Product Description
Mechanism of Action
R&D Progress
GS 9310/11
Product Description
Mechanism of Action
R&D Progress
GS 9411
Product Description
Mechanism of Action
R&D Progress
GS 9667
Product Description
Mechanism of Action
R&D Progress
Gilead Sciences, Inc. – Pipeline Analysis
Gilead Sciences, Inc. – Pipeline Products by Therapeutic Class
Gilead Sciences, Inc. – Pipeline Products By Target
Gilead Sciences, Inc. – Pipeline Products by Route of Administration
Gilead Sciences, Inc. – Pipeline Products by Molecule Type
Gilead Sciences, Inc. – Recent Pipeline Updates
Gilead Sciences, Inc. – Dormant Projects
Gilead Sciences, Inc. – Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
GS 7340
GS 9005
GS 9132
Gilead Sciences, Inc. – Company Statement
Gilead Sciences, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nov 23, 2010: Gilead Sciences Submits NDA To FDA For Truvada And TMC278 For HIV
Oct 30, 2010: Gilead's GS 9190 And GS 9256 In Combination With Standard Of Care Therapies Achieve Substantial Viral Suppression In Phase II HCV Study
Oct 21, 2010: Gilead Reports Cayston Superior To Tobramycin Inhalation Solution In Six-Month Head-To-Head Cystic Fibrosis Study
Sep 03, 2010: Gilead Sciences Submits European Marketing Application For Truvada And TMC278 For Treatment Of HIV Infection
Sep 03, 2010: Gilead Sciences Submits European Marketing Application for Once-Daily Single-Tablet Regimen of Truvada and TMC278 for the Treatment of HIV Infection
Jul 19, 2010: Gilead Sciences Announces Results From Clinical Trial Of Tenofovir Gel For Women's HIV Prevention
Jul 19, 2010: Gilead Sciences Announces Results From Clinical Trial Of Tenofovir Gel For Women's HIV Prevention
Jun 24, 2010: Gilead Sciences Receives CHMP Positive Opinion For Pharmacological Stress Agent Rapiscan
Jun 18, 2010: Gilead's Phase III Study Of Cayston Versus Tobramycin Inhalation Solution In Cystic Fibrosis Patients Achieves Co-Primary Efficacy Endpoint Of Non-Inferiority
Apr 27, 2010: Gilead Finalizes Selection of Bioequivalent Formulation for the Fixed-Dose Regimen of Truvada and Tibotec Pharmaceuticals' TMC278
Financial Deals Landscape
Gilead Sciences, Inc., Deals Volume Summary, 2004 to YTD 2010
Gilead Sciences, Inc., Deals Summary By Region, 2004 to YTD 2010
Gilead Sciences, Inc., Deals Summary, 2004 to YTD 2010
Gilead Sciences, Inc. Detailed Deal Summary
Asset Purchase
Graceway Pharmaceuticals Acquires Licensing Rights From Gilead Sciences Acquisition
Gilead Sciences Acquires CV Therapeutics
Gilead Sciences Acquires Nycomed Limited
Gilead Sciences Acquires Myogen
Gilead Sciences Acquires Raylo Chemicals From Degussa
Gilead Sciences Acquires Corus Pharma
Equity Offering
Corus Pharma Completes Private Placement Of $25 Million
Debt Offering
Parion Sciences Completes Private Placement Of $5 Million With Gilead Sciences
Gilead Sciences Completes Private Placement Of $650 Million
Advanced Chemical Transport Partners With Gilead Sciences
Gilead Sciences Enter Into An Agreement With Merck
Bristol-Myers Squibb Signs Co-Marketing Agreement With Gilead Sciences
Praecis Pharmaceuticals Enters Into Technology Transfer Agreement With Gilead Sciences
GliazoSmithKline Signs An Agreement With Myogen
Bristol-Myers Squibb Enters Into Agreement With Gilead Sciences
Genelabs Technologies Enters Into Collaboration Agreement With Gilead Sciences
Southern Research Enters Into Co-Development Agreement With Gilead Sciences
ActivX Biosciences Enters Into Research Agreement With Gilead Sciences
Licensing Agreements
GliazoSmithKline Enters Into Licensing Agreement With Gilead Sciences
Gilead Sciences Enters Into License Agreement With Tibotec Pharmaceuticals
Gilead Sciences Amends Licensing Agreement With Aspen Pharmacare
Gilead Sciences Enters Into Licensing Agreement With LG Life Sciences
Gilead Sciences Enters Into An Agreement With Parion Sciences
Gilead Sciences Enters Into Licensing Agreement With CONRAD And IPM
Gilead Sciences Enters Into Licensing Agreement With Alkem Laboratories
Gilead Sciences Enters Into Licensing Agreement With Medchem
Gilead Sciences Enters Into Licensing Agreement With Matrix Laboratories
Gilead Sciences Enters Into Licensing Agreement With J. B. Chemicals & Pharmaceuticals
Gilead Sciences Enters Into Licensing Agreement With Ranbaxy Laboratories
Gilead Sciences Enters Into Licensing Agreement With FDC
Gilead Sciences Enters Into Licensing Agreement With Aurobindo Pharma
Gilead Sciences Enters Into Licensing Agreement With Shasun Chemicals & Drugs
Gilead Sciences Enters Into Licensing Agreement With Emcure Pharmaceuticals
Gilead Sciences Enters Into Licensing Agreement With Strides Arcolab
Gilead Sciences Enters Into Licensing Agreement With Hetero Drugs
Diatos Enters Into Licensing Agreement With Gilead Sciences
GliazoSmithKline Enters Into Licensing Agreement With Myogen
Gilead Sciences Enters Into Licensing Agreement With Aspen Pharmacare
Gilead Sciences Enter Into Licensing Agreement With Japan Tobacco
Achillion Pharmaceuticals Enters Into Licensing Agreement with Gilead Sciences
Medarex Amends Collaboration And Licensing Agreement With Gilead Sciences
CyDex Pharmaceuticals Enters Into Licensing Agreement With Gilead Sciences
4 AZA Bioscience Enters Into Licensing Agreement With Gilead Sciences
Gilead Sciences Terminates Licensing Agreement With Roche
Gilead Sciences Terminates Agreement With Emory University And University of Georgia
Appendix
Methodology
Coverage
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Order by Fax - using the form below  
Order by Post - print the order form below and send to  
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name:  Gilead Sciences, Inc. - Product Pipeline Review - Q4 2010
Web Address:  http://www.researchandmarkets.com/reports/1463880/
Office Code:  SC6IOKTB

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 500</td>
</tr>
<tr>
<td>Site License:</td>
<td>USD 1000</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr  □  Mrs  □  Dr  □  Miss  □  Ms  □  Prof  □
First Name:  ___________________________  Last Name:  ___________________________
Email Address:  ___________________________
Job Title:  ___________________________
Organisation:  ___________________________
Address:  __________________________________________
City:  __________________________________________
Postal / Zip Code:  ___________________________
Country:  ___________________________
Phone Number:  __________________________________________
Fax Number:  __________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB9853308313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp